IMR Press / FBE / Volume 5 / Issue 1 / DOI: 10.2741/E606

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Is the H4 receptor a new drug target for allergies and asthma?

Show Less
1 Palau Pharma S.A., Avda Cami Reial 51-57, 08184 Palau-solita i Plegamans, Barcelona, Spain
2 Unitat de Farmacologia Clinica, Hospital de Sabadell, Corporacio Sanitaria Parc Tauli, Department Farmacologia, Toxicologia i Terapeutica, Universitat Autonoma de Barcelona, Spain

*Author to whom correspondence should be addressed.


Front. Biosci. (Elite Ed) 2013, 5(1), 178–187;
Published: 1 January 2013

Histamine H4 receptor (H4R) has become a promising target for immuno-inflammatory diseases, such as allergic rhinitis, asthma or dermal allergies. Its distribution pattern in immune cells and the preclinical data obtained from different biological systems using diverse histamine H4 modulators (1) suggest a key role of H4R in immunity and in inflammatory cell trafficking. Recent results with UR-63325, the first H4R antagonist from which clinical data has been reported (2), confirm the feasibility of complete H4R blocking in humans without limiting safety concerns. Also, H4R blockade results in clear pharmacodynamic effects in relevant human cells, e.g. eosinophils. It is believed that allergic rhinitis and asthma are manifestations of one unique syndrome in two parts of the respiratory tract. Dermal allergies are also recognized as related manifestations in a different location. The coexistence of allergic-related diseases in the same patients could permit a single treatment approach e.g.. the systemic use of H4R antagonists. Further clinical studies are needed to establish the role of H4R antagonists in the treatment of allergic diseases.

H4 Histamine Receptor
JNJ- 39758979
Back to top